A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder

Current Medical Research and Opinion

Volumn 24, Issue 4, 2008, Pages 1115-1121

  Armstrong, Edward P ^a   Malone, Daniel C ^a   Erder, M Haim ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Cost utility; Depression; Duloxetine; Escitalopram; Pharmacoeconomics

Indexed keywords

DULOXETINE; ESCITALOPRAM; PLACEBO;

CONFERENCE PAPER; COST UTILITY ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; EJACULATION DISORDER; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MEDICAL FEE; NAUSEA; QUALITY ADJUSTED LIFE YEAR; REMISSION; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT FAILURE; TREATMENT OUTCOME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; THIOPHENES; TREATMENT OUTCOME; UNITED STATES;

EID: 42549141815     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X273309     Document Type: Conference Paper

References (42)

1. Panzarino PJ Jr, Nash DB. Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am J Manag Care 2001;7:173-84
2. Croom KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. Pharmacoeconomics 2004;18:469-73
3. Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005;3:449-56
4. Lexapro® prescribing information. Forest Pharmaceuticals, Inc. Revised February 2005
5. Cymbalta® prescribing information. Eli Lilly and Company. PV 3608 AMP
6. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
7. Croghan TW. The controversy of increased spending for anti-depressants. Health Affairs 2001;20:129-35
8. Fochtmann LJ, Gelenberg AJ. Guideline watch: practice guideline for the treatment of patients with major depressive disorder, 2nd edition. Arlington, VA: American Psychiatric Association, 2005. Available from http://www.psych.org/ psych_pract/treatg/pg/MDD.watch.pdf [Last accessed 19 Dec 2007]
9. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15
10. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70
11. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily versus placebo in the acute treatment of major depression. J Psychiatric Res 2002;36:383-90
12. Goldstein DJ, Lu Y, Dedce MJ, et al. Duloxetine in the treatment of depression. A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99
13. Burt VK, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 2005;46:345-54
14. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-31
15. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64:1237-44
16. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6
17. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Internat Clin Psychopharmacol 2003;18:211-7
18. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Clin Psychopharmacol 2002;17:95-102
19. Ventura D, Armstrong EP, Skrepnek GH, Erder MH. Escitalopram versus sertraline in the treatment of major depressive disorder. A randomized clinical trial. Curr Med Res Opinion 2007;23:245-50
20. Bech P, Tanghoj P, Cialdella P, et al. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Internat J Neuropsychopharmacol 2004;7:283-90
21. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6
22. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opinion 2005;21:1659-68
23. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-67
24. Kasper S, Swart HD, Andersen HF. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005;13:884-91
25. Lancon C, Sapin C, Note L, Farisse J. Escitalopram and citalopram in outpatients suffering from severe major depressive disorder: a prospective, observational, eight-week study. Int J Neuropsychopharmacol 2004;7(Suppl 1):S349 [abstract]
26. Montgomery SA, Huusom AKT, Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
27. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
28. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depression Anxiety 2005;21:26-32
29. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-32
30. McLaughlin TP, Eaddy MT, Grudzinski AN. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges. Clin Ther 2004;26:115-24
31. Physician fee schedule, Center for Medicare and Medicaid Services. Available from http://www.cms.hhs.gov/physicians/mpfsapp/step0.asp [Last accessed 3 Jan 2005]
32. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19:305-10
33. Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002;5:91-107
34. Francois C, Toumi M, Aaakhus AM, Hansen K. A pharmacoconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Eur J Health Econ 2003;4:12-9
35. Wade AG, Toumi I, Hemels MEH. A probabilistic cost-effectveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opinion 2005;21:631-41
36. Kulp W, Schulenburg JMGV, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ 2005;6:317-21
37. Hemels MEH, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opinion 2004;20:869-78
38. Baardewijk MV, Vis PMJ, Einarson TR. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder. Curr Med Res Opinion 2005;21:1271-79
39. Vis PM, Baardewijk MV, Einarson TR. Duloxetine and venlaaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005;39:1798-807
40. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol Clin Exp 2005;20:327-41
41. Mallinckrodt CH, Raskin J, Wohlreich MM, et al. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry 2004;4:26
42. Gartlehner G, Hansen RA, Thieda P, et al. Comparative effectveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Agency for Heahhcare Research and Quality (AHRQ) Publication No. 07-EHC007-EF. January 2007